ArticleBMC neurology2026
A preliminary analysis of the inflammatory protein landscape in the CSF of mid- to late-stage Parkinson's disease: associations with motor severity and subtypes.
Article in BMC neurology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeParkinson's disease (PD) is a progressive neurodegenerative disorder in which neuroinflammation is recognized as a contributor to clinical progression. This study aimed to characterize the cerebrospinal fluid (CSF) inflammatory profile in mid- to late-stage PD patients and identify specific inflammatory proteins with potential clinical relevance to motor symptoms and disease severity.
methodsIn this preliminary retrospective cross-sectional study, CSF samples were obtained from 25 patients with mid- to late-stage PD undergoing evaluation for deep brain stimulation (DBS) (mean disease duration: 10.24 ± 4.65 years) and 15 non-PD controls (essential tremor or dystonia) undergoing identical surgical procedures. The levels of 92 inflammation-related proteins were quantified using the Olink proximity extension assay (PEA). Based on the identified differentially expressed proteins (DEPs), we next performed preliminary exploratory comparisons of inflammatory profiles between the postural instability and gait difficulty (PIGD, n = 10) and tremor-dominant (TD, n = 10) PD subtypes. Additionally, preliminary correlation analyses were performed between the DEPs and Movement Disorder Society-Unified Parkinson's Disease Rating Scale Part-III (MDS-UPDRS-III) scores to generate preliminary observations with limited clinical inference.
resultsUsing the Olink platform, 28 DEPs were identified between the PD and non-PD groups (p < 0.05). Subsequent protein-protein interaction network analysis identified IFN-γ as the central hub. Exploratory descriptive analyses of TD and PIGD subgroups are provided in Additional file 1: Supplementary Figure S1. Among all DEPs, IL-10RB (r = 0.440, 95% CI [0.054, 0.711], p = 0.028), CD8A (r = 0.415, 95% CI [0.024, 0.696], p = 0.039), and CXCL9 (r = 0.414, 95% CI [0.023, 0.696], p = 0.040) showed moderate correlations with MDS-UPDRS-III scores.
conclusionIn profiling 92 CSF inflammation-related proteins from 25 advanced PD patients (Hoehn-Yahr 3-4) and 11 controls, we identified 28 upregulated DEPs. IFN-γ emerged as a topologically connected hub in protein-protein interaction networks, and three proteins (IL-10RB, CD8A, CXCL9) showed moderate correlations with motor scores. As cross-sectional descriptive observations, these findings establish a preliminary framework to generate hypotheses for future mechanistic validation and biomarker discovery, while no functional causality can be inferred from the present results.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.